EMPOWER-Lung 1 (NCT03088540), a multicenter, open-label, randomized phase 3 trial, evaluated cemiplimab as monotherapy versus chemotherapy alone in patients with advanced NSCLC and PD-L1 expression in ≥50% of tumor cells [13, 15]. Here, CD274 is linked to neoplasm.